tiprankstipranks
Advertisement
Advertisement

BIIB Stock Latest News

Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
Weekend UpdatesTvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
58m ago
BIIB
FCEL
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
PremiumMarket News
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
22h ago
EE
GH
Biogen Shareholders Back Board, Auditor and Pay Policies
PremiumCompany Announcements
Biogen Shareholders Back Board, Auditor and Pay Policies
2d ago
8K
BIIB
Needham upgrades Biogen on pipeline potential, stabilizing core business
PremiumThe Fly
Needham upgrades Biogen on pipeline potential, stabilizing core business
5d ago
BIIB
Biogen upgraded to Buy from Hold at Needham
PremiumThe Fly
Biogen upgraded to Buy from Hold at Needham
5d ago
BIIB
Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
PremiumCompany AnnouncementsBiogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
8d ago
BIIB
Biogen granted Breakthrough Therapy Designation for salanersen by FDA
Premium
The Fly
Biogen granted Breakthrough Therapy Designation for salanersen by FDA
9d ago
BIIB
UCB, Biogen announce dapirolizumab pegol data at EULAR
Premium
The Fly
UCB, Biogen announce dapirolizumab pegol data at EULAR
9d ago
BIIB
Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet
PremiumThe Fly
Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet
12d ago
BIIB
Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors
PremiumCompany Announcements
Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors
15d ago
BIIB
DNLI
Biogen price target raised to $227 from $222 at RBC Capital
PremiumThe Fly
Biogen price target raised to $227 from $222 at RBC Capital
17d ago
BIIB
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
PremiumThe Fly
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
22d ago
BIIB
DNLI
Biogen Earnings Call Signals Confident, Investment-Heavy Transition
PremiumCompany AnnouncementsBiogen Earnings Call Signals Confident, Investment-Heavy Transition
24d ago
BIIB
Immunic appoints Michael Bonney as chair
Premium
The Fly
Immunic appoints Michael Bonney as chair
25d ago
BIIB
IMUX
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
Premium
Ratings
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
29d ago
BIIB
Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
PremiumRatings
Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
29d ago
BIIB
Cisco upgraded, Doximity downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Cisco upgraded, Doximity downgraded: Wall Street’s top analyst calls
29d ago
AOS
PHR
Biogen resumed with an Outperform at Evercore ISI
PremiumThe Fly
Biogen resumed with an Outperform at Evercore ISI
29d ago
BIIB
Biogen price target raised to $225 from $214 at Piper Sandler
PremiumThe Fly
Biogen price target raised to $225 from $214 at Piper Sandler
29d ago
BIIB
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
PremiumRatingsHold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
29d ago
BIIB
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
Premium
Ratings
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
29d ago
BIIB
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
Premium
Ratings
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
29d ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >